Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 4/2018

01.08.2018 | Therapy in Practice

The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia

verfasst von: Ruairi Wilson, Caroline Osborne, Christina Halsey

Erschienen in: Pediatric Drugs | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Prophylactic eradication of central nervous system (CNS) leukaemia is the current standard of care in treating childhood acute lymphoblastic leukaemia (ALL). This is conventionally achieved through regular lumbar punctures with intrathecal injections of methotrexate into the cerebrospinal fluid (CSF). Ommaya reservoirs are subcutaneous implantable devices that provide a secure route of drug delivery into the CSF via an intraventricular catheter. They are an important alternative in cases where intrathecal injection via lumbar puncture is difficult. Among UK Paediatric Principal Treatment Centres for ALL we found considerable variation in methotrexate dosing when using an Ommaya reservoir. We review the current safety and theoretical considerations when using Ommaya reservoirs and evidence for methotrexate dose adjustments via this route. We conclude by summarising the pragmatic consensus decision to use 50% of the conventional intrathecal dose of methotrexate when it is administered via Ommaya reservoir in front-line ALL therapy.
Literatur
1.
Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257–68.CrossRefPubMed
2.
Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199–209.CrossRefPubMed
3.
Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21(2):184–8.CrossRefPubMed
4.
Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(60):2730–41.CrossRefPubMedPubMedCentral
5.
Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4:42.CrossRefPubMedPubMedCentral
6.
Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol. 2009;10(10):957–66.CrossRefPubMed
7.
Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104(9):2690–6.CrossRefPubMed
8.
Möricke A, Reiter A, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477–89.CrossRefPubMed
9.
Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896–904.CrossRefPubMedPubMedCentral
10.
Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;2(7315):983–4.CrossRefPubMed
11.
Meijer L, Walker D, Slavc I. Intra-cerebrospinal fluid therapy for leptomeningeal metastases in medulloblastoma. In: Kombogiorgas DA, editor. The medulloblastoma book. Hauppauge: Nova Science Publishers, Inc.; 2014.
12.
Peyrl A, Chocholous M, Azizi AA, Czech T, Dorfer C, Mitteregger D, Gojo J, Minichmayr E, Slavc I. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neurooncol. 2014;120(1):139–45.CrossRefPubMed
13.
Mead PA, Safdieh JE, Nizza P, Tuma S, Sepkowitz KA. Ommaya reservoir infections: a 16-year retrospective analysis. J Infect. 2014;68(3):225–30.CrossRefPubMed
14.
Young GA, Milliken S, Jurd J, Poulgrain P, Vincent PC. The intraventricular reservoir in the treatment of neurological disease secondary to hematological malignancy: an eight year experience. Aust NZ J Med. 1986;16(3):373–7.CrossRef
15.
Lishner M, Perrin RG, Feld R, Messner HA, Tuffnell PG, Elhakim T, Matlow A, Curtis JE. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med. 1990;150(1):173–6.CrossRefPubMed
16.
Browne MJ, Dinndorf PA, Perek D, Commers J, Bleyer WA, Poplack DG, Pizzo PA. Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J. 1987;6(2):182–9.CrossRefPubMed
17.
Bleyer WA, Pizzo PA, Spence AM, Platt WD, Benjamin DR, Kolins CJ, Poplack DG. The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer. 1978;41(6):2431–7.CrossRefPubMed
18.
Packer RJ, Zimmerman RA, Rosenstock J, et al. Focal encephalopathy following methotrexate therapy: administration via a misplaced intraventricular catheter. Arch Neurol. 1981;38:450–2.CrossRefPubMed
19.
Colamaria V, Carabello R, Borgna-Pignatti C, et al. Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine; a complication of Ommaya reservoir: case report and review of the literature. Child’s Nerv Syst. 1990;6:231–5.CrossRef
20.
Kennedy BC, Brown LT, Komotar RJ, McKhann GM 2nd. Frameless stereotactic ommaya reservoir placement: efficacy and complication comparison with frame-based technique. Stereotact Funct Neurosurg. 2015;93(6):415–8.CrossRefPubMed
21.
Weiner GM, Chivukula S, Chen CJ, Ding D, Engh JA, Amankulor N. Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. Clin Neurol Neurosurg. 2015;130:61–6.CrossRefPubMed
22.
Morgenstern PF, Connors S, Reiner AS, Greenfield JP. Image guidance for placement of ommaya reservoirs: comparison of fluoroscopy and frameless stereotactic navigation in 145 patients. World Neurosurg. 2016;93:154–8.CrossRefPubMedPubMedCentral
23.
Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178–84.CrossRefPubMed
24.
Bhojwani D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–59.CrossRefPubMedPubMedCentral
25.
Bond J, Hough R, Moppett J, Vora A, Mitchell C, Goulden N. ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial. Leukaemia. 2013;27(4):1765–9.
26.
Cheung YT, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Hematol. 2016;3(10):e456–66.CrossRef
27.
Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231–9.CrossRefPubMed
28.
Krull KR, et al. Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2016;34(22):2644–53.CrossRefPubMedPubMedCentral
29.
Jacola LM, et al. Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. J Clin Oncol. 2016;34(11):1239–47.CrossRefPubMedPubMedCentral
30.
Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, Gurney JG, Kimberg C, Krasin MJ, Pui CH, Robinson LL, Hudson MM. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukaemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407–15.CrossRefPubMedPubMedCentral
31.
Kanellopoulos A, et al. Neurocognitive outcome in very long-term survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. Pediatr Blood Cancer. 2016;63(1):133–8.CrossRefPubMed
32.
Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol. 1998;16(5):1712–22.CrossRefPubMed
33.
Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol. 2016;78(5):1093–6.CrossRefPubMedPubMedCentral
34.
Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer. 1972;8(4):409–14.CrossRefPubMed
35.
Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–6.CrossRefPubMed
36.
Bleyer WA, Poplack DG, Simon RM. “Concentration × time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978;51(5):835–42.PubMed
37.
Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol. 2003;25(2):114–7.CrossRefPubMed
38.
Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children’s Leukemia Cooperative Group. J Clin Oncol. 1997;15(5):1824–30.CrossRefPubMed
39.
Mehta BM, Glass JP, Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res. 1983;43:435–8.PubMed
40.
Ells LJ, Hancock C, Copley VR, et al. Prevalence of severe childhood obesity in England: 2006–2013. Arch Dis Child. 2015;100(7):631–6.CrossRefPubMed
41.
42.
Steinherz P, Jereb B, Galicich J. Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol. 1985;3(9):1217–26.CrossRefPubMed
43.
Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous system leukaemia: prolonged remission with the ommaya reservoir. Med Pediatr Oncol. 1979;6:2017–213.CrossRef
44.
Iacoangeli M, Roselli R, Pagano L, et al. Intrathecal chemotherapy for treatment of overt meningeal leukaemia: comparison between intraventricular and traditional intralumbar route. Ann Oncol. 1995;6:377–82.CrossRefPubMed
45.
Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36–51.CrossRefPubMed
46.
Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical–biochemical correlates. J Clin Invest. 1969;48(11):2140–55.CrossRefPubMedPubMedCentral
47.
Ettinger LJ, Chervinsky DS, Freeman AI, Creaven PJ. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin’s lymphoma. Cancer. 1982;50(9):1676–82.CrossRefPubMed
48.
Mauer AM. Cell Kinetics and practical consequences for therapy of acute leukaemia. N Engl J Med. 1975;293:389–93.CrossRef
49.
Strother DR, Glynn-Barnhart A, Kovnar E, Gregory RE, Murphy SB. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol. 1989;7(11):1741–7.CrossRefPubMed
50.
Kuo AH-M, Xenophon Y, Galicich H, Fried J, Clarkson BD. Proliferative kinetics of central nervous system (CNS) leukaemia. Cancer. 1975;36:232–9.CrossRefPubMed
51.
Tsuchiya J, Moteki M, Shimano S, Shinonome S, Suda T, Omine M, Maekawa T. Proliferative kinetics of the leukaemic cells in meningeal leukaemia. Cancer. 1978;42:1255–62.CrossRefPubMed
52.
53.
Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289(15):770–3.CrossRefPubMed
54.
Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. J Clin Oncol. 1985;3(1):19–24.CrossRefPubMed
55.
Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73(5):641–7.CrossRefPubMed
56.
Chiro GD, Hammock MK, Bleyer WA. Spinal descent of cerebrospinal fluid in man. Neurology. 1976;26(1):1–8.CrossRefPubMed
57.
Larson S, Schall G, Di Chrio G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med. 1971;12:555–7.PubMed
Metadaten
Titel
The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia
verfasst von
Ruairi Wilson
Caroline Osborne
Christina Halsey
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 4/2018
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-018-0298-9

Weitere Artikel der Ausgabe 4/2018

Pediatric Drugs 4/2018 Zur Ausgabe

Review Article

Dose-Dependent Teratology in Humans: Clinical Implications for Prevention

Original Research Article

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial

Review Article

Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies

Review Article

Using Lithium in Children and Adolescents with Bipolar Disorder: Efficacy, Tolerability, and Practical Considerations

Review article

Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter

Original Research Article

Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise